Amendment No. 7 to Schedule TO

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DQie2qwr20GrYuSxUbgrVCE06Qy/Tb0k3d3kV4sRpLjb30QHH5u0sovUW6teehT7 fuOH5RwEZi8p8QZEN3HWlg== 0001193125-10-226461.txt : 20101008 0001193125-10-226461.hdr.sgml : 20101008 20101008083557 ACCESSION NUMBER: 0001193125-10-226461 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20101008 DATE AS OF CHANGE: 20101008 GROUP MEMBERS: ZEUS ACQUISITION CORPORATION SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ZYMOGENETICS INC CENTRAL INDEX KEY: 0001129425 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911144498 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-78019 FILM NUMBER: 101115071 BUSINESS ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-442-6600 MAIL ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ZYMOGENETICS INC CENTRAL INDEX KEY: 0001129425 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911144498 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-78019 FILM NUMBER: 101115072 BUSINESS ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-442-6600 MAIL ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 SC TO-T/A 1 dsctota.htm AMENDMENT NO. 7 TO SCHEDULE TO Amendment No. 7 to Schedule TO

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

Amendment No. 7

ZYMOGENETICS, INC.

(Name of Subject Company (Issuer))

ZEUS ACQUISITION CORPORATION

(Offeror)

A Wholly Owned Subsidiary of

BRISTOL-MYERS SQUIBB COMPANY

(Offeror)

(Names of Filing Persons (identifying status as offeror, issuer or other person))

COMMON STOCK, NO PAR VALUE

(Title of Class of Securities)

98985T109

(CUSIP Number of Class of Securities)

Sandra Leung, Esq.

General Counsel & Corporate Secretary

P. Joseph Campisi, Jr., Esq.

Vice President & Assistant General Counsel

Bristol-Myers Squibb Company

345 Park Avenue

New York, New York 10154

(212) 546-4000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

Copies to:

David Fox, Esq.

Daniel Wolf, Esq.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

(212) 446-4800

CALCULATION OF FILING FEE


Transaction Valuation(1)		Amount of Filing Fee(2)
$883,869,654		$63,020

(1)

Calculated solely for purposes of determining the filing fee. The calculation assumes the purchase of 86,584,072 shares of common stock, without par value, and 99,516 shares of common stock subject to restricted stock units, in each case, at $9.75 per share. The transaction value also includes the aggregate offer price for 8,500,698 shares issuable pursuant to outstanding options with an exercise price less than $9.75 per share, which is calculated by multiplying the number of shares underlying such outstanding options at each exercise price therefor by an amount equal to $9.75 minus such exercise price.

(2)	Calculated in accordance with Exchange Act Rule 0-11 by multiplying the transaction value by 0.0000713.

x	Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.


Amount Previously Paid: $63,020		Filing Party: Bristol-Myers Squibb Company and Zeus Acquisition Corporation
Form of Registration No.: Schedule TO		Date Filed: September 10, 2010

¨	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

x	Third-party tender offer subject to Rule 14d-1.

¨	Issuer tender offer subject to Rule 13e-4.

¨	Going-private transaction subject to Rule 13e-3.

x	Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. x

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

¨	Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

¨	Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 7 to the Tender Offer Statement on Schedule TO (the “Schedule TO”) amends and supplements the Schedule TO relating to the tender offer by (i) Zeus Acquisition Corporation, a Washington corporation (“Purchaser”) and a wholly-owned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and (ii) Parent, for all of the outstanding common stock, without par value (the “Shares”), of ZymoGenetics, Inc., a Washington corporation (the “Company”), at a price of $9.75 per share net to the seller in cash without interest and less required withholding taxes, if any, upon the terms and conditions set forth in the offer to purchase dated September 10, 2010 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, together with any amendments or supplements, collectively constitute the “Offer.”

Items 1 through 9 and 11

Items 1 through 9 and Item 11 of the Schedule TO, which incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented to include the following:

“At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the Depositary to Parent, as of the expiration of the Offer, approximately 82,605,529 Shares were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 Shares subject to guaranteed delivery procedures. Purchaser has accepted for payment all Shares validly tendered and not validly withdrawn. The Shares validly tendered and not validly withdrawn represent approximately 94.9% of the Shares outstanding.

The full text of the press release issued by Parent regarding the expiration of the Offer and the announcement that Purchaser has accepted for payment all Shares validly tendered and not validly withdrawn is set forth as Exhibit (a)(16) hereto and is incorporated by reference herein.”

Item 12. Exhibits.

Regulation M-A Item 1016

Item 12 of the Schedule TO is amended and supplemented by adding the following exhibits:


Exhibit No.

(a)(16)		Press Release issued by Bristol-Myers Squibb Company, dated October 8, 2010.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


ZEUS ACQUISITION CORPORATION

By		/S/ P. JOSEPH CAMPISI, JR.
Name:		P. Joseph Campisi, Jr.
Title:		Vice President

Date:		October 8, 2010

BRISTOL-MYERS SQUIBB COMPANY

By		/S/ P. JOSEPH CAMPISI, JR.
Name:		P. Joseph Campisi, Jr.
Title:		Vice President and Assistant General Counsel

Date:		October 8, 2010

EXHIBIT INDEX



Exhibit No.

(a)(1)(A)		Offer to Purchase, dated September 10, 2010.*

(a)(1)(B)		Letter of Transmittal (including Internal Revenue Service Form W-9).*

(a)(1)(C)		Notice of Guaranteed Delivery.*

(a)(1)(D)		Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*

(a)(1)(E)		Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*

(a)(1)(F)		Joint Press Release of ZymoGenetics, Inc. and Bristol-Myers Squibb Company, dated September 7, 2010 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission dated September 9, 2010).*

(a)(1)(G)		Summary Advertisement as published on September 10, 2010.*

(a)(5)		Press Release issued by Bristol-Myers Squibb Company, dated September 10, 2010.*

(a)(6)		Class Action Complaint dated September 9, 2010 (Vereen v. ZymoGenetics, Inc., et al.).*

(a)(7)		Class Action Complaint dated September 9, 2010 (Krivan v. ZymoGenetics, Inc., et al.).*

(a)(8)		Class Action Complaint dated September 9, 2010 (Jaung v. the ZymoGenetics, Inc., et al.).*

(a)(9)		Class Action Complaint dated September 15, 2010 (Mesa v. ZymoGenetics, Inc., et al.).*

(a)(10)		Press Release issued by Bristol-Myers Squibb Company, dated September 28, 2010.*

(a)(11)		Amended Class Action Complaint dated September 17, 2010 (Mesa v. ZymoGenetics, Inc., et al.).*

(a)(12)		Amended Class Action Complaint dated September 21, 2010 (Krivan v. ZymoGenetics, Inc., et al.).*

(a)(13)		Class Action Complaint dated September 20, 2010 (Eyster v. ZymoGenetics, Inc., et al.).*

(a)(14)		Class Action Complaint dated September 23, 2010 (Zhou v. Bruce L.A. Carter, Ph.D., et al.).*

(a)(15)		Memorandum of Understanding, dated as of September 29, 2010 (incorporated by reference to Exhibit (a)(1)(L) to Amendment No. 4 to the Schedule 14D-9 filed by ZymoGenetics, Inc. with the Securities and Exchange Commission on October 5, 2010).*

(a)(16)		Press Release issued by Bristol-Myers Squibb Company, dated October 8, 2010.

(d)(1)		Agreement and Plan of Merger, dated as of September 7, 2010, by and among ZymoGenetics, Inc., Bristol-Myers Squibb Company, and Zeus Acquisition Corporation (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by ZymoGenetics, Inc. with the Securities and Exchange Commission on September 9, 2010).*

(d)(2)		Form of Tender and Support Agreement, by and among Bristol-Myers Squibb Company, Zeus Acquisition Corporation and Stockholder, dated September 7, 2010 (incorporated by reference to Exhibit 2.2 to the Form 8-K filed by ZymoGenetics, Inc. with the Securities and Exchange Commission on September 9, 2010).*

*	Previously filed.

EX-99.(A)(16) 2 dex99a16.htm PRESS RELEASE Press Release

LOGO

Bristol-Myers Squibb Completes Tender Offer for ZymoGenetics, Inc.

with 94.9% of Shares Tendered

(NEW YORK, October 8, 2009) – Bristol-Myers Squibb Company (NYSE: BMY) announced today that the tender offer, through its wholly owned subsidiary Zeus Acquisition Corporation, for all outstanding shares of common stock of ZymoGenetics, Inc. (NASDAQ: ZGEN) expired at midnight (New York City time) on October 7, 2010, and was not extended. The depositary for the tender offer has advised Bristol-Myers Squibb that, as of the expiration of the tender offer, shareholders of ZymoGenetics tendered approximately 82,605,529 shares of ZymoGenetics common stock, including approximately 1,501,981 shares subject to guaranteed delivery procedures, representing approximately 94.9% of the ZymoGenetics shares outstanding. According to the terms of the tender offer, shares that were validly tendered and not validly withdrawn have been accepted for payment.

Bristol-Myers Squibb intends to complete the acquisition of ZymoGenetics through what is known as a “short-form merger,” that is, without a vote or meeting of the remaining ZymoGenetics shareholders. Each of the remaining shares of ZymoGenetics common stock will be converted into the right to receive $9.75 per share, in cash, without interest and less any required withholding taxes, which is the same amount per share which was paid in the tender offer. The merger is expected to occur as soon as practicable. Following the merger, ZymoGenetics will become a wholly-owned subsidiary of Bristol-Myers Squibb, and the common stock of ZymoGenetics will no longer list on NASDAQ.

Georgeson Inc. acted as information agent for Bristol-Myers Squibb. Morgan Stanley & Co. Incorporated is serving as financial advisor to Bristol-Myers Squibb in connection with the transactions and served as the dealer-manager for the tender offer. Kirkland & Ellis LLP is acting as legal counsel to Bristol-Myers Squibb.

This press release contains “forward-looking statements” relating to the acquisition of ZymoGenetics by Bristol-Myers Squibb. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers

Squibb’s Annual Report on Form 10-K for the year ended December 31, 2009, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words “future”; “anticipate”; “potential”; “believe”; or similar statements are forward-looking statements. Risks and uncertainties include uncertainties as to the timing of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; as well as risks detailed from time to time in ZymoGenetics’ public disclosure filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2009, subsequent quarterly filings on Form 10-Q and the Solicitation/Recommendation Statement filed in connection with the tender offer. The information contained in this release is as of October 7, 2009.

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of ZymoGenetics. Bristol-Myers Squibb Company and Zeus Acquisition Corporation have filed a tender offer statement with the SEC, and have mailed an offer to purchase, forms of letter of transmittal and related documents to ZymoGenetics shareholders. ZymoGenetics has filed with the SEC, and has mailed to ZymoGenetics shareholders, a solicitation/recommendation statement on Schedule 14D-9. These documents contain important information about the tender offer and shareholders of ZymoGenetics are urged to read them carefully.

These documents are available at no charge at the SEC’s website at www.sec.gov. The tender offer statement and the related materials may be obtained for free by directing a request by mail to Georgeson Inc., 199 Water Street, 26^th Floor, New York, New York 10038 or by calling toll-free (800) 509-1078. In addition, a copy of the offer to purchase, letter or transmittal and certain other related tender offer documents (once they become available) may also be obtained free of charge from Bristol-Myers Squibb by directing a request to: Public Affairs, Telephone No.: (609) 252-6579; E-Mail: jennifer.mauer@bms.com.

Contacts


Media:		Jennifer Fron Mauer, Telephone No.: (609) 252-6579; E-Mail: jennifer.mauer@bms.com

Investors:		Teri Loxam, Telephone No.: (609) 252-3368, teri.loxam@bms.com
		Suketu Desai, Telephone No.: (609) 252-5796, suketu.desai@bms.com

GRAPHIC 3 g105647g_press.jpg GRAPHIC begin 644 g105647g_press.jpg M_]C_X0@G17AI9@``34T`*@````@`#0$```,````!`KP```$!``,````!`%H` M``$"``,````#````J@$&``,````!``(```$2``,````!``$```$5``,````! M``,```$:``4````!````L`$;``4````!````N`$H``,````!``(```$Q``(` M```<````P`$R``(````4````W`$[``(````)````\(=I``0````!````_``` M`30`"``(``@`*):@```G$``HEJ```"<0061O8F4@4&AO=&]S:&]P($-3-2!7 M:6YD;W=S`#(P,3`Z,3`Z,#@@,#$Z,3,Z-#4`='=E7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4& M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/2\R^ZM MH;C[?4/=_`&OT6RW?8Z/H;D`YN5O9L=6]HCU!!&A@>U^[V/]WLK>U-FLKQ[7 MWO<6MOAI/:0(V[OY6W_"_HE6J;7CO;[VEUC0Q@:!)U_D>^S=O]MW_;JFC&/# MM?T^UCD3?]KK67LKQWY#I-;&%Y@28`W'VH&'U.C+L])K7UV&IE[6V``FNR=C MQM+OW?H?32^QO'3;,1CO>^M[07PV7N.UOTJ&>C75_A-_P"G38Q@0;EUT/\`8DF=BAT=ME@?N@.&QQ:=S2V2 M.[=WTV?RTU5M=U3;JG!]=@#F.'!!X(66>DY8RFVM+-KC9_P7J(5'1,RIE5?Z-I8*`VUKC-0I=^E]%NW_M4W_P`^?IO5 M2X(?O*XI?NN@[JV*.F'JD6'':SU'`-)>&@P[]']+V*3NIX@RL;%:XOMRV.LJ MV"6[&C=ZKW_1:QV[V?OJK5T[-JZ:W':]GJ-;`JG]%/J>KZF_9ZOT$')Z"QKV M;''[$&Y/VAI<38UMS-K*L38SVUT>[T:_\%_@T>''9UZRK_N57/33H/[7;26% M5TS.O./DY1#G6,:[(8USJBVP.K>RUGT]CG4U,JN:WW_N/_26)5]&S*QC.9L% M[+7ON>7NHAP1_?"N*7[KHW=3IJR3BA MEEUK&L?:*F[MC+'.JKL>)W.;N99_-^I]!6UE]3Z?EY>3794RNNRES'8V:'.% MM8G]88^L-_356-&WT?4]*W_"?0WJBSIV97ELJ#9R&UBUUNY^RTUY++_TED>V MZZK?[??_`-LI"$2!1H]5&4@3I?9V\G-IQ1-H?`+!+6.(_2/;0SWQL^F__,]Z M?[75]L^QZ^MZ?K#0[=N[T_I_O;EC.Z-U(UD36XP3L-CRTG[7]N:SW-_[C_HM M_P"__P`$FLZ)U!V[::VFUEK6.WNF@V6MR*O2AHW^AM_>_G?^!1X(?O=T&4OW M>CK9/4:<>YF/M?=D/:ZP4U#<[8WZ5CI+6,9N]C=SOTC_`.;5BJP6U,L`[8?8YUE=K+-K_P#2V-L9M52W MI74;+GO^TV^L'N!%9K]/["&Q_-[_`,__`*_Z?KIHC$@:UIO_`&)N5[=7 M;27/5=%S,<,L.W]$*"XML>7?HZ7TYA9[?YRYSF_\?_.6_I%#&Z5G685?I-8V MB^BECZ;'.#MS:K`[*ES?T&0ZRRIEW^%V5?SGK(^W']\*XS^Z](DL']CY;G>I MDD.W/;Z[A8_<:OLOV2]K=/I.O_3;?^N_SJO]'IN;B-MR"3?<`7D@@EK1Z=.Y MCB=C_2:UUO\`PN]"40!8E:1(DU5/_]#U-VW:=T;>\\*+?0W>S;N[1$KY921" MGZJ3+Y6204_5*2^5DDE/U2DOE9))3]4I+Y6224_5*2^5DDE/U2DOE9))3]4I M+Y6224_5*2^5DDE/U2DOE9))3__9_^T/7%!H;W1O`X#AP%/2\+:Y$3RN:;FV#A"24T$.@`````` MR0```!`````!```````+<')I;G1/=71P=70````$`````%!S=%-B;V]L`0`` M``!);G1E96YU;0````!);G1E`````$-L7!E M`````$YO;F4````)=&]P3W5T```"6````&C0`8``'_ MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D) M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P, M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%`"@`P$B``(1 M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$` M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,! M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56 M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$# M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:F MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]+S+[JVAN/M]0]W\`:_1 M;+=]CH^AN0#FY6]FQU;VB/4$$:&![7[O8_W>RM[4V:RO'M?>]Q:V^&D]I`C; MN_E;?\+^B5:IM>.]OO:76-#&!H$G7^1[[-V_VW?]NJ:,8\.U_3[6.1-_VNM9 M>RO'?D.DUL87F!)@#X[6_2H9 MZ-=7^$W_`*=-C&!!N770_P!B29V*'1VV6!^Z`X;'%IW-+9([MW?39_+356UW M5-NJ<'UV`.8X<$'@A99Z3EC*;:TLVMR'6-!<7-%3_2]2IU#V_3VU;J7UO9Z- MG_!>HA4=$S*F55_HVE@H#;6N,U"EWZ7T6[?^U3?_`#Y^F]5+@A^\KBE^ZZ#N MK8HZ8>J18<=K/4<`TEX:##OT?TO8I.ZGB#*QL5KB^W+8ZRK8);L:-WJO?]%K M';O9^^JM73LVKIK<=KV>HUL"J?T4^IZOJ;]GJ_00^YY>YS'-=; MZFU];V[G/]#^8M8^M^-;_P`!ZB'!']\*XI?NNC=U.FK).*&676L:Q]HJ;NV, MLJ+.G9E>6RH-G(;6+76[G[+37DLO_261[;KJM_M]_\`VRD( M1(%&CU492!.E]G;RZ:#9:W(J]*&C?Z&W][^=_X%'@A^]W092_=Z.MD]1IQ[F8^U M]V0]KK!34-SMC?I6.DM8QF[V-W._2/\`YM6*K!;4RP!S0]H<&N!:X2)AS7?1 ME=1LN>]SF%[[3 M;ZP>X$5FOT_L(;'\WO\`S_\`K_I^NFB,2!K6F_\`8FY7MU=M)<]5T7,QPRP[ M?T0H+BVQY=^CI?3F%GM_G+G.;_Q_\Y;^D4,;I6=9A5^DUC:+Z*6/ILLC[FYN(VW()-]P!>2""6M'IT[F.)V/])K76_P#" M[T)1`%B5I$B354__T/4W;=IW1M[SPHM]#=[-N[M$2OEE)$*?JI,OE9)!3]4I M+Y6224_5*2^5DDE/U2DOE9))3]4I+Y6224_5*2^5DDE/U2DOE9))3]4I+Y62 M24_5*2^5DDE/_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@ M`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\` M&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N M8V]M+W!D9B\Q+C,O(B!X;6QN&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO&%P M+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA M<"\Q+C`O&UP.D-R96%T;W)4;V]L/2)!9&]B92!0 M:&]T;W-H;W`@0U,U(%=I;F1O=W,B('AM<#I-;V1I9GE$871E/2(R,#$P+3$P M+3`X5#`Q.C$S.C0U+3`T.C`P(B!X;7`Z0W)E871E1&%T93TB,C`Q,"TQ,"TP M-U0R,SHT,SHR.2TP-#HP,"(@>&UP.DUE=&%D871A1&%T93TB,C`Q,"TQ,"TP M.%0P,3HQ,SHT-2TP-#HP,"(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!- M33I$;V-U;65N=$E$/2)X;7`N9&ED.C)!0CDW-$1#.$5$,D1&,3$X.#="04(R M.#)$,#0P1C$W(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C`W,C$T,D0S M.4%$,D1&,3$X1##IX;7!M971A/B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(#P_ M>'!A8VME="!E;F0](G0``9&5S8P`````````2D!\@'Z M`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL" MU0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3 M`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X% M#044%]@8&!A8&)P8W!D@&609J M!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@( M"P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/ M">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+ MX0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3 M#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0 MFQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-# M$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86 M219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK M&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P< M]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8 M(,0@\"$<(4@A=2&A(B>K)]PH#2@_*'$HHBC4 M*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-]1B)&9T:K1O!'-4=[1\!(!4A+ M2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY. MMT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H M5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5< M-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-# M8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J M]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI&>J5[ M!'MC>\)$7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7 M@[J$'82`A..%1X6KA@Z&I+CDTV3MI0@E(J4])5? MEAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$ MJ3>IJ:H_R#W( MO,DZR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI1NG0ZEOJY>MP MZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q$S M%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&I+16 MTU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_(B8J+C(V.CX*3E)66EYB9FINGM\?7Y_(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,! M``(1`Q$`/P#[V:CJ,&EV5S?W1(AM4+NJBK-05XJ*[D]ADL<#DEPAA.8@++SC M3?S(OM16:=O+GU"T5U6WFN;H*SC-%_,*2_UR30]4T*;2)6D9+2Z]19HF*J#QD8<>#-V7?*\W9_!#CC( M2'VKCUO%/@E$@_CF]*KFN$CRRMF[EMBKN1]OEBA2>XBC:-))4C>8\848@%R.H4'J?EDN$E;KG MLZ:Z@M_3^L3QP^JP2+FP7DQZ**D5)]L`C(\NBD@.EN(K>-I9Y4@C05>60A5' MS)Z80"30%K:JKJZJZL&5@"K#<$'H01@2OQ5V*J3R!%+N0B*"7<[``=23VIBM M@#=#6NI6%\)#8WMO>"*@D,$JR<2>E>)-*Y*<)1Y@L8R$N1M'9%DLY'OM@M3L MLCGBE+B.5',9XR!2#Q/@:=#A((KS0#?)T<\B24$B*K*)6_9(/T9LX8H&'%(&0OD-Z[Z/'O^8`Y;C%JB<5U3VCRIJ\NN>7]-U2=%26ZC/,*6()1BO(H1>Z;:Q)'(UQ:A@6=HQ4A5 M=?'.LP3X\UV:\T#1=#? M7=$T+0-,OKCS1<7OH2WUOJ%G+)$Z1"(D2,8J,"PH37-+G[/CB`G.?#*:M-%QI% MSJU_(86G]8QO8I=-'(&F45:CD5Z#+-1V9*1RSG/B,#O0Y;?57=TVMKPZ[@C" M,8\,2-B3MS^F^]3\K_F7YJMKS5]%O].37->UWSKK&F^6;;ZT%B@M;)5>7U7] M.JI"-AL2QQU.@Q$"=F,8PB3MSOEUWM<&KR`RB19E.0C?]'G\$K\S^;?\5>:/ MR^M+K3VTCS#Y-_,"WT_5[5)C+&5N+&YD22.10O-)$4D!AMENFTHPXLLKN,L= MQVWY@=_GS7)F&6<8R%2A,`]VX9)^<+^7/S)\DRZ%INL`RMK6G6YU.V+QRV5Q M)*?2E1J*0>2CIVS%[-&72YN,C;A)H]0.]GK\L-1C,82Y$`UY_!X3^:/F/S)Y MP_+"_P!%\PK=Z9<_EOJME8>=G`:*+4[U+N..#TF%.<3H1*Q'?8YM=!AA@SC) M``C(#*(_FQK?[=@X.IS9,N*4)@@XS5]^^WPKF^DQ^:5S97/FS0/\*I!J_E+4 M+*PT_2A>J/KMK=H&2ZC/I#@BK6HH:$4KFF/9T2(2$[$@3=?-VT=7+BE M#AHQ(H7]0/4)3IWYYRZH+>]LO*,]WI&H6&I:C9W$-P&EBM[`,TKNWWX>K3#M(SG48@@@GGO\=NO1!G\^-1@T3RC MY@U7R:F@Z3YTWTO5;R_)M(*IRC6\F2W*P&4[(6^'Q(R?\D#Q)XQ/B,#N`-_A MONQGVE.`C*4*$CSO8>\UU9_^8GEO6/S#_+?4]`TW4?\`#6L:U:6\L-RC^JD< MB.DYA9XRI9'X\&*'=22,U^BSPTN<3D..,3\_U.7J\,M1@,0>$D;==WA/ECSW MY:\B/YCDUK\O?\'_`)IZ-:V&GW_EC39:6>KQ32K#:W%G)3@R,Y^)BO)>]C:A^=.JZ%J'F#3-=\ MFK#<^7I]#AN6M;X31NNMR&))%8PJ:1L-Q3?MF)B[,CEC$PG?%Q=/YOQ;I]HS MQR(E`;H>6M1>/RAYJ\OZ:TEG?FV:8ZA<)Z%R&1 M0>"O0/&:\AMD]+V=/T2$AZX2.X_F\QS^39/6\4IPX3Z3$<^?%UY,5T#SG+^7 MM[^;FMRZ0^HZ#'YY:/59EN6]6V6Y=4,L<;JP8*6!*@C+L^F.I&&%T>#;;RY6 MX^/4'#+)+G'CH^2SR-YSD\AVGGR_ETQ]1\L3?F--975\MTWJ6B7[6T<B"OV$H`2SA:T&8V,Y]=Z92L1!))WH!NR#%I?5$;DT!WE(O,?YZS^5#KN MG:KY,GE\QZ%+I[2:5:W:/%/9ZC,L$=S%.T:UXNP#+QV\IV-Z+CT[BWC M]5([A1$JH9%!Z.Q7H1E7\G7A.3BJ@#1%<^[?H@:X>(($#C::6ZTI9F,+KZ8"B80,$:O6@[Y;D[,A`R!RCT MU>W25;CW6PQ]H2F(G@-2NO?&_OIFGE'\S%\XKY4ET[1RL'F'3)-1OY#.&-@R M'CZ,@"?$Q:H[9CZG0^!QB4MXFOZWF/)MP:PY>`B/U"SY>3U3->YS_]'[H>:= M,>YLGO;6V%W?64;F.WH*RHP^.,'L3V/8YE:3*(RX9'8M&?'Q#;F\5LKC2]7, MZ7>F&$VBQ6_Z+ND=!;JAY24]CXYO?ZFW`?$EP M\)][WZWMH;6"&W@3A#`@CB0=E44&:&4C(DGF7;T\>E_)30)'\SPQZUK$&D^= M+M[WS-I*7/[NYDDIS^+CR`8"A`/3-I_+&2H`QB90%1-;@=/DZV/9>./&!8$S MRK2ORZT'1-0U^_TQKBU_Q!IMGI4]HLG[F&VL(GAMUA2GP<$N_;W4X_\FPX1$F1B.E[;?I1C_D_ MY?\`K=YJ%MJ.H6=Y+K$VNZ9-%*!]2O;E!'.T.VZR*/B4U!RO^4IT!(`@`1WZ M@;HOR=\MQW&G7[7=_)J=EKB^8[G46F_>W6H+&84>;; M=51BH44&YPCM3(!(5&I1X:KD+O9E^1CL;-@\7O/FRGS)Y*TSS':6EFTLVEQV ME]!J%;#C$9);<\HPY"[J#VRC!K)8I<1J6U;MF?31RBC?,';;DA?/_P"7VC_F M)Y>E\M:S/MEI9\<0":(WO:V6;`,L> M$W3&T\DR:C^:$'FK4]/(A\KZ&-)TO57<>I?/<_%,TB#8J@J!4;$FF72U8CIC M"/.4K(_FUW./^7$L_B$?2"!\5;2ORETW0]/U+0]+UW4[3RY?)=1Q:*DB>G`M MV&#JK\>95>9X@DTP9>TIY)"[WK;C\I;"7ROH_D^+S M!JD6AZ9IKZ5_WL@U/R!IM]Y2TCRC9:CJ6BVF@)9II%_97!2ZA%BH2+]Z:EJJ*-7KE./63 MCEEE(!,KL$;;MD]-&4!`$BJJN>S#[O\`(_R[K#ZQ>^8]4U'7]=U2&"WM]>N) M%6>RCM9?6A%MQ`5")!R)IOF3#M?+C,1`",19KH;[W'/9N.9)F22:WZBNYBR? ME?J.N^;/S%T_S,U_+H6L:?H"Z3YH]1$N'O-*:23U5"]"KL"*BAWR[\_#%CQR MQ@"0,KCTJ3CC1SG/)&1/"1&CYC]3(Y_R,T:ZCUL7?F+5[B?S%JFEZSJMT\JE MWN])=9(&7X?A7D@)4;&F51[6G'AJ,?2#$;=)ZUG4K[1=0UU/,EUY>FD4V[7\;(Z,:`$HK1J0O M389$]J9*%``B/#=;TO\`)T"3Q$D$W1Y6S7SGY%T;SO:6,6HF:TU#1[E;W0M9 MM&].ZLKE>DD+T-*C8@[$=V8LDL"Q@*&W()-:C+X]I2@?W<1$'F!>_O MW82T8G]9)Y5Y$=1MS2[4?R0T;64U6?5]:I,8M.D$UO;H* M42,.H)`ZY9'M?)`@1`$0#0K;?F?>@Z&)%DDDUO[NB-UC\G=*UH>>!<:WJ<0\ M_7^GZAJWI.H]-]-$2PK#L>*D0)4>V1AVG*`Q@1'[L$#;OYWWL9]GPGQV?K() M^'>>;3SBM]8:!>^;!JL.FAT$6J00)&8FF*U(7F@)7VS)U.O M$!`PHD0X?ZKCX=$9\<9D\)E=,GL/R-T?3+[3+NR\PZM%#H6K7VKZ'8F13%;S MZCR,X^S5UJYX@G;*I=K2E$@PCZ@`?ARZMO\`)L8D&,B*-^6Z.TC\F]*T6+R- M%;Z[J4B>0+R\O=)$CJ3*]]ZGK"9M:N])70]1\WZM/J-QI2OS%O&32.,4V&U20NU3D-?J/$, M(@V(1J^\KHM-X8E([&1O^QZYF"YS_]+[]??@50E^K[>MQKVY\:_CAA=[6@TO M'IT''[/[-*4I^K`5CRV5L*5NWX8KT;VV_#%6MO?VQW5VWOUQ*NVP;*[:GM3; M"K9I].*J?PUWK7Z.GT8HW^U?M_3QQ2WMCNK1P%7;4W^G"K6WO^&!6]J85=M[ MXKT;VQ5WW^V`JUMA*N\?QQ5VWO[XJU\-.]-L"GS;V_#'97;>_MA0U\._]F`> '23YK\*O_V3\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----